Fructosamine Test Market Size, Share, and Industry Analysis, By Application (Type-1 Diabetes, Type-2 Diabetes, and Others), By Sample (Blood Serum, Blood Plasma, and Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Regional Forecast till 2032

The global fructosamine test market is witnessing significant growth owing to the increasing prevalence of type 1 and type 2 diabetes, resulting in the growing demand for diagnostic procedures. Fructosamine test helps in the estimation of blood glucose levels among diabetic patients, further preventing the health problems that can be caused by this condition.

• According to data published by the World Health Organization (WHO), the number of people with diabetes rose from 200 million in 1990 to 830 million in 2022 worldwide.

Fructosamine Test Market Driver

Increasing Prevalence of Diabetes to Drive Market Growth

The rising prevalence of diabetes among the patient population is resulting in a growing number of patient admissions, further supporting the growing diagnostic procedures, such as the fructosamine test, among others, in the market. This, along with rising preference toward health monitoring among the population and growing product launches for fructosamine tests, is expected to support the growing adoption of these products.

• According to 2024 statistics published by the Centers for Disease Control & Prevention (CDC), it was reported that about 38 million people have diabetes in the U.S.

Download Free sample to learn more about this report.

According to data published by the International Diabetes Federation (IDF), it was reported that the prevalence of diabetes is 33.5 million in the U.S., 3.0 million in Canada, 4.0 million in the U.K., and 6.2 million in Germany.

Fructosamine Test Market Restraint

Limited Awareness in Emerging Countries May Hinder Market Growth

There is a growing demand for fructosamine tests to measure the blood glucose levels. However, limited awareness about the benefits of these tests, coupled with the number of clinical laboratories in emerging countries such as Brazil, China, among others, is expected to hamper the adoption rate of these tests.

• According to 2021 statistics published by the American Society for Clinical Pathology, there are about 7,624 clinical laboratories in Mexico.

Fructosamine Test Market Opportunity

Demand for Point-of-Care Tests to Provide Opportunities for Market Growth

There is a growing preference toward point-of-care testing owing to the benefits of these tests among the population, such as faster diagnosis and treatment, reduced hospital stays, among others in the market. The growing number of benefits is resulting in the rising adoption rate for point-of-care fructosamine tests among patients globally.

• According to a 2022 survey published by the National Center for Biotechnology Information (NCBI), it was reported that approximately 90% of respondents amongst 285 respondents believe that point-of-care testing improves the management of medical conditions among patients in the U.S.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Disorders, By Key Countries, 2023
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, and Partnerships)
• Impact of COVID-19 on the Market

Analysis by Application

On the basis of application, the market is subdivided into type-1 diabetes, type-2 diabetes, and others.

The type-2 diabetes segment holds a substantial market share in 2023. The growing prevalence of type 2 diabetes among patients is resulting in the rising product adoption, boosting the demand for fructosamine tests.

• According to 2021 statistics published by the Australian Institute of Health and Welfare (AIHW), it was reported that about 1.2 million have type 2 diabetes in Australia.

Analysis by Sample

In terms of sample, the market is divided into blood serum, blood plasma, and others.

The blood serum segment accounts for a significant market share in 2023. The segmental growth is due to the rising number of fructosamine tests performed with blood serum, owing to its accuracy among the patient population. This, along with the growing focus of key players to introduce fructosamine tests specific to blood serum, is likely to support the segmental growth.

• According to a 2023 study published by the National Center for Biotechnological Information (NCBI), the fructosamine test done with blood serum showed accurate results amongst 1,227 respondents in the U.S.

Analysis by End User

Based on end user, the market is subdivided into hospitals & clinics, diagnostic laboratories, and others.

The hospitals & clinics segment dominates the market in 2023. The growth is owing to the surging number of hospitals and clinics and awareness about the fructosamine test, further resulting in the growing adoption rate for these tests in the market.

• According to 2022 statistics published by the Australian Institute of Health and Welfare, it was reported that there are about 697 hospitals in Australia.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounts for the largest market share in 2023. The growth is owing to several factors, including the soaring prevalence of diabetes, developed healthcare infrastructure, and growing number of hospitals, among others.

• According to 2024 statistics published by Definitive Healthcare, there are about 7,378 active hospitals in the U.S.

Additionally, Europe is the second-largest market for fructosamine tests. The rising prevalence of type 1 and type 2 diabetes among patients, further resulting in a growing demand for diagnostic tests, including fructosamine tests. This, along with the rising advancements in these diagnostic tests is further expected to contribute to the growth of the market in the region.

• According to 2023 statistics published by Diabetes UK, it was reported that more than 5.6 million people have diabetes in the U.K.

On the other hand, Asia Pacific is also expected to grow at a considerable CAGR during the forecast period. The growth is due to the rising number of hospitals and diagnostic centers offering novel diagnostic tests such as fructosamine tests.

Key Players Covered

The global market is fragmented and has several major players.

The report includes the profiles of the following key players:

• Randox Laboratories Ltd. (U.K.)
• Weldon Biotech, Inc. (India)
• Abbexa (U.K.)
• Hoffmann-La Roche Ltd. (Switzerland)
• Eurolyser Diagnostica GmbH (Austria)
• LifeSpan BioSciences, Inc. (U.S.)
• Fortress Diagnostics (U.K.)
• Abcam Limited (U.K.)

Key Industry Developments

• In October 2023, Abbexxa collaborated with Nulife Consultants & Distributors (Pvt.) Ltd. as a distributor for its life science products in India. This helped the company strengthen its presence in the Asia Pacific region.
• In April 2022, Abcam Limited established a new regional hub in Singapore with an aim to expand its geographical presence in the country. This helped the company to increase its research and development activities in life science and healthcare.